ADMA BIOLOGICS INC (ADMA)
US0008991046 - Common Stock
Taking everything into account, ADMA scores 5 out of 10 in our fundamental rating. ADMA was compared to 588 industry peers in the Biotechnology industry. ADMA has only an average score on both its financial health and profitability. ADMA has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year ADMA has reported negative net income.
ADMA had a positive operating cash flow in the past year.
In the past 5 years ADMA always reported negative net income.
In the past 5 years ADMA reported 4 times negative operating cash flow.
1.2 Ratios
ADMA's Return On Assets of -8.58% is amongst the best of the industry. ADMA outperforms 89.73% of its industry peers.
ADMA's Return On Equity of -20.88% is amongst the best of the industry. ADMA outperforms 87.16% of its industry peers.
The Return On Invested Capital of ADMA (6.12%) is better than 96.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.58% | ||
| ROE | -20.88% | ||
| ROIC | 6.12% |
ROA(3y)-17.8%
ROA(5y)-25.57%
ROE(3y)-38.32%
ROE(5y)-77.03%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Operating Margin, with a value of 8.38%, ADMA belongs to the top of the industry, outperforming 95.21% of the companies in the same industry.
ADMA's Gross Margin of 34.44% is fine compared to the rest of the industry. ADMA outperforms 78.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.38% | ||
| PM (TTM) | N/A | ||
| GM | 34.44% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ADMA is destroying value.
ADMA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ADMA has been increased compared to 5 years ago.
ADMA has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 4.16 indicates that ADMA is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.16, ADMA is in the better half of the industry, outperforming 78.77% of the companies in the same industry.
ADMA has a debt to FCF ratio of 34.20. This is a negative value and a sign of low solvency as ADMA would need 34.20 years to pay back of all of its debts.
ADMA has a Debt to FCF ratio of 34.20. This is amongst the best in the industry. ADMA outperforms 93.84% of its industry peers.
ADMA has a Debt/Equity ratio of 0.97. This is a neutral value indicating ADMA is somewhat dependend on debt financing.
ADMA has a Debt to Equity ratio of 0.97. This is in the lower half of the industry: ADMA underperforms 77.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.97 | ||
| Debt/FCF | 34.2 | ||
| Altman-Z | 4.16 |
ROIC/WACC0.65
WACC9.35%
2.3 Liquidity
A Current Ratio of 5.16 indicates that ADMA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.16, ADMA is in line with its industry, outperforming 55.65% of the companies in the same industry.
ADMA has a Quick Ratio of 1.69. This is a normal value and indicates that ADMA is financially healthy and should not expect problems in meeting its short term obligations.
ADMA has a Quick ratio of 1.69. This is in the lower half of the industry: ADMA underperforms 78.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.16 | ||
| Quick Ratio | 1.69 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 58.06% over the past year.
The Revenue has grown by 67.58% in the past year. This is a very strong growth!
Measured over the past years, ADMA shows a very strong growth in Revenue. The Revenue has been growing by 72.31% on average per year.
EPS 1Y (TTM)58.06%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-33.33%
Revenue 1Y (TTM)67.58%
Revenue growth 3Y82.9%
Revenue growth 5Y72.31%
Revenue growth Q2Q47.87%
3.2 Future
The Earnings Per Share is expected to grow by 44.57% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 10.52% on average over the next years. This is quite good.
EPS Next Y333.42%
EPS Next 2Y143.78%
EPS Next 3Y87.85%
EPS Next 5Y44.57%
Revenue Next Year30.19%
Revenue Next 2Y23.3%
Revenue Next 3Y19.01%
Revenue Next 5Y10.52%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ADMA. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 21.29 indicates a rather expensive valuation of ADMA.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 96.40% of the companies listed in the same industry.
ADMA's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 21.67.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 21.29 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ADMA is valued cheaper than 95.03% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 93.84% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 386.04 | ||
| EV/EBITDA | 51.83 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ADMA's earnings are expected to grow with 87.85% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y143.78%
EPS Next 3Y87.85%
5. Dividend
5.1 Amount
ADMA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ADMA BIOLOGICS INC
NASDAQ:ADMA (4/24/2024, 7:00:00 PM)
After market: 6.48 +0.02 (+0.31%)6.46
-0.08 (-1.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.47B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 21.29 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.58% | ||
| ROE | -20.88% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 8.38% | ||
| PM (TTM) | N/A | ||
| GM | 34.44% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.78
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.97 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.16 | ||
| Quick Ratio | 1.69 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)58.06%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y333.42%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)67.58%
Revenue growth 3Y82.9%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y